PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of
PN-943 450 mg twice daily [BID] and PN-943 150 mg BID, compared with placebo BID, in subjects
with moderate to severe active Ulcerative Colitis (UC).